Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy - Top-Institutions - MDSpire

Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy

By
Jeongin Yoo
Dong Ho Lee
Do-Youn Oh
Jeesun Yoon
Sang Hyub Lee
In Rae Cho
Woo Hyun Paik
May 28, 2026
0 min

European Radiology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Mass General Cancer Center

Boston, MA
Key Differentiators
- Oncology
#2

Cleveland Clinic

Cleveland, OH
Key Differentiators
- Oncology
#3

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Oncology
#4

Charité–Universitätsmedizin Berlin

Berlin, Germany
Key Differentiators
- Oncology
#5

University of Washington

Seattle, WA
Key Differentiators
- Oncology

Original Source(s)

European Radiology

Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy

by Jeongin Yoo, Dong Ho Lee, Do-Youn Oh, Jeesun Yoon, Sang Hyub Lee, In Rae Cho, Woo Hyun Paik
May 28, 2026

Related Content

Frontiers In Oncology

A Case Report of follicular dendritic cell sarcoma

by Lijiao Wang, Tingshu Jiang
June 18, 2026

Dana-Farber

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.